Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA – Get Free Report) has been assigned a consensus rating of “Buy” from the twelve brokerages that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have assigned a buy rating and three have given a strong buy rating to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $46.38.
A number of equities analysts have issued reports on DMRA shares. Wall Street Zen upgraded Damora Therapeutics, Inc. Common Stock from a “sell” rating to a “hold” rating in a report on Sunday. Guggenheim initiated coverage on Damora Therapeutics, Inc. Common Stock in a research note on Friday. They issued a “buy” rating and a $59.00 price target for the company. TD Cowen upgraded shares of Damora Therapeutics, Inc. Common Stock to a “strong-buy” rating in a research report on Monday, August 24th. Wedbush reiterated an “outperform” rating and issued a $40.00 price target on shares of Damora Therapeutics, Inc. Common Stock in a research report on Tuesday, September 29th. Finally, HC Wainwright reissued a “buy” rating and set a $45.00 price objective on shares of Damora Therapeutics, Inc. Common Stock in a research note on Tuesday, July 21st.
Get Our Latest Stock Report on Damora Therapeutics, Inc. Common Stock
Damora Therapeutics, Inc. Common Stock News Roundup
- Positive Sentiment: Wall Street Zen raised its rating on DMRA to “Hold,” an improvement that may modestly bolster sentiment. Article: Damora Therapeutics Stock Bumped Up to Hold by Wall Street Zen
- Neutral Sentiment: Guggenheim initiated coverage, adding analyst attention; the headline does not specify its rating or price target. Article: Guggenheim Initiates Coverage on Damora Therapeutics
- Neutral Sentiment: DMRA crossed above its 50-day moving average, a potentially constructive technical signal, but the article also references an analyst downgrade. The downgrade’s details were not provided. Article: Damora Stock Crosses Above Fifty Day Moving Average After Analyst Downgrade
- Negative Sentiment: HC Wainwright lowered its 2026 and 2027 EPS forecasts, including its FY2027 estimate from a loss of $1.59 to $1.70 per share. It retained a “Buy” rating and $45 price target, tempering the negative read-through. MarketBeat coverage of Damora Therapeutics
Damora Therapeutics, Inc. Common Stock Price Performance
Shares of Damora Therapeutics, Inc. Common Stock stock opened at $23.70 on Monday. Damora Therapeutics, Inc. Common Stock has a 12 month low of $4.95 and a 12 month high of $38.33. The business has a fifty day simple moving average of $22.72 and a 200 day simple moving average of $25.70. The stock has a market cap of $1.47 billion, a PE ratio of -7.03 and a beta of 1.52.
Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA – Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The company reported ($0.40) EPS for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.12. Analysts expect that Damora Therapeutics, Inc. Common Stock will post -2.09 EPS for the current fiscal year.
Insider Buying and Selling
In other news, CEO Jennifer Jarrett bought 12,500 shares of the stock in a transaction on Friday, September 25th. The stock was purchased at an average price of $20.23 per share, with a total value of $252,875.00. Following the completion of the purchase, the chief executive officer owned 512,500 shares of the company’s stock, valued at approximately $10,367,875. This trade represents a 2.50% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 0.40% of the company’s stock.
Hedge Funds Weigh In On Damora Therapeutics, Inc. Common Stock
A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Braidwell LP acquired a new position in shares of Damora Therapeutics, Inc. Common Stock in the 2nd quarter valued at $42,146,000. Seven Fleet Capital Management LP bought a new stake in shares of Damora Therapeutics, Inc. Common Stock in the 2nd quarter valued at $7,398,000. Squarepoint Ops LLC bought a new stake in shares of Damora Therapeutics, Inc. Common Stock in the 2nd quarter valued at $303,000. Finally, Arizona State Retirement System acquired a new stake in Damora Therapeutics, Inc. Common Stock during the 2nd quarter worth $260,000. 14.20% of the stock is owned by institutional investors.
About Damora Therapeutics, Inc. Common Stock
Galecto, Inc, a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.
Recommended Stories
- Five stocks we like better than Damora Therapeutics, Inc. Common Stock
- Lemonade’s Revenue Soars 73%—So Why Did Its Stock Turn Sour After Earnings?
- Anthropic’s S-1 Strengthens the Case for Broadcom’s AI Growth
- After the Midterms, Which of These 3 Defense ETFs Looks Strongest?
- The Ugly Truth Behind SoundHound’s Q3 Results
Receive News & Ratings for Damora Therapeutics Inc. Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Damora Therapeutics Inc. Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.
